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1. Do Your Patients Really Know How to 
Use an Inhaler?
By Donald D. Accetta, MD, MPH – Physician Member of 
Massachusetts Board of Registration in Pharmacy
Over 50% of patients do not use their asthma inhalers 
properly. For many of these patients, they were never taught 
by the health care provider who prescribed the medication, or 
the health professional used faulty technique. But even when 
properly instructed, studies have shown that the technique 
deteriorates over time and needs periodic review. Mistakes 
range from the common (using an empty inhaler, not shaking 
the inhaler before each puff, spraying multiple times for one 
inhalation, etc) to the truly bizarre (such as the patient who 
kept both an inhaler and handgun under the pillow . . . you can 
guess the rest of this sad story). Surprisingly, there is a similar 
failure rate for the newer dry powder inhalers (such as Advair® 
and Pulmicort®). Many elderly individuals have difficulty 
operating some of the devices due to limited dexterity.
Metered dose inhalers (MDI) contain the medication 
either as a suspension (needs to be shaken before each 
activation) or solution (no shaking needed). The MDI can 
be activated as often as every 15-20 seconds. 
The general technique for using an MDI is usually sim-
ilar for all brands. While it is useful to read the package 
insert, it is better to actually see the procedure performed 
and then have your own technique critiqued by a knowl-
edgeable person. The major pharmaceutical companies 
train all their respiratory division representatives and they, 
in turn, can teach other health professionals. If you ask, 
the representatives are generally quite willing to review 
the technique and give you a demonstration. The specifics 
of the inhaler technique will vary depending on the type 
of inhaler used (suspension, solution, dry powder, breath 
activated) and will not be reviewed here, but are enclosed 
as an insert in all inhalers. 
There are a variety of accessory devices such as the 
Aerochamber®, Aerochamber with Mask®, and Inspi-
rease®, which can be used with the MDI to assist those 
who have difficulty using an inhaler. These devices also 
generally will increase lung deposition of the drug while 
decreasing the amount retained in the oropharynx. 
There are two relatively new inhaler devices on the 
market (Foradil Aerolizer®, Spiriva®), which present a 
rather unique problem. These two medications come 
as individual doses in a blister pack. They need to be 
inserted into the device (the Aerolizer or HandiHaler®, 
respectively), crushed, and then inhaled. There have 
been reports of patients swallowing rather than inhaling 
these medications. Thus, the pharmacist should make 
certain that instructions for usage are clear and that the 
patient understands that these are to be inhaled (see the 
“Patient Safety Tips of the Month” article on page four 
of this Newsletter for additional information).
2. Letter from the President
By Karen Ryle, RPh, MS, President
In my previous letter, I promised to update you on the 
recommendations from the National Association of Boards 
of Pharmacy® (NABP®) Task Force to Best Reduce Medi-
cation Errors in Community Pharmacy Practice. Since the 
recommendations are quite lengthy, I will only share some 
of the highlights. 
Recommendation: NABP will work with the states to 
enact “peer review programs and freedom from discovery 
protection” regulation and legislation to encourage the re-
porting, data collection, and analysis of medication errors.
Recommendation: NABP will aggressively pursue Food 
and Drug Administration (FDA) to prevent the use of product 
nomenclature, packaging, and labeling that may significantly 
contribute to medication errors.
Recommendation: NABP will work with the schools 
and colleges of pharmacy to incorporate patient safety 
and quality into the curriculum of pharmacy, nursing and 
medical schools. NABP will explore the possibility of in-
corporating specific competency statements regarding the 
National Boards of Pharmacy Licensure Examination and 
a request will be forwarded to the Pharmacy Technician 
Certification Board concerning the Pharmacy Technician 
Certification Examination
Page 2
National Pharmacy Compliance News
(Applicability o?
and can only be ascertained by examining the law of such state or jurisdiction.)
New Board Will Oversee Management of 
Drug Safety Monitoring
Food and Drug Administration (FDA) has unveiled a program 
that aims to improve oversight of drug safety monitoring and to 
bolster openness in agency product review and decision making. 
Included is the creation of an independent Drug Safety Oversight 
Board, made up of medical experts from FDA and other gov-
ernment agencies. Also planned are Web postings of emerging 
drug data and risk information as well as written materials that 
provide targeted drug safety information to the public. For more 
information, see www.fda.gov/oc/factsheets/drugsafety.html.
ACPE Changes Provider Criteria Regarding 
Drug and Device Manufacturers
In early 2005, the Accreditation Council for Pharmacy Educa-
tion (ACPE) ceased accepting applications from pharmaceutical 
and biomedical device manufacturers seeking accreditation as 
providers of continuing education (CE). Effective July 1, 2005, 
the organization will no longer recognize pharmaceutical and 
biomedical device manufacturers as accredited providers. In ad-
dition, any CE issued by a pharmaceutical or device manufacturer 
after June 30, 2005, is not valid. These changes were approved by 
the ACPE Board of Directors at its January 2005 meeting after 
the organization determined that manufacturers could not meet 
both ACPE’s requirements and the recommended restrictions as 
stated in a Compliance Program Guidance for Pharmaceutical 
Manufacturers published by the Office of the Inspector General 
of the United States (OIG).
In 2003, OIG stated that manufacturers could be subjected 
to liability under federal statutory provisions if they maintain 
any influence over CE subject matter or presenters, or provide 
funding for attendees or other incentives with respect to CE 
attendance. Strict compliance with OIG’s guidelines would 
relegate manufacturers to solely providing educational grants 
to CE providers in order to be free of liability. Meanwhile, 
ACPE’s Criteria for Quality require that the CE provider 
control the content speakers or authors of a CE program, 
putting ACPE’s requirements in opposition to OIG’s guide-
lines; hence, ACPE, out of responsibility to health regulatory 
boards, the profession, and the public, must now accredit 
only those providers who are in compliance with the ACPE 
criteria and the OIG guidelines. 
In accordance with ACPE’s new policies, organizations with a 
commercial interest and any proprietary entity producing health 
care goods or services, with the exception of nonprofit or govern-
ment organizations and non-health care-related companies, will 
not be eligible for ACPE accreditation status.
For more information, contact ACPE Executive Di-
rector Peter Vlasses at 312/664-3575, or via e-mail at 
pvlasses@acpe-accredit.org.
Let’s Get to the ‘Point’: 
Prescription Misinterpretations 
Due to Decimal Points
This column was prepared by the Institute for 
Safe Medication Practices (ISMP). ISMP is an 
independent nonprofit agency that works closely 
with United States Pharmacopeia (USP) and FDA in analyz-
ing medication errors, near misses, and potentially hazardous 
conditions as reported by pharmacists and other practitioners. 
ISMP then makes appropriate contacts with companies and 
regulators, gathers expert opinion about prevention measures, 
then publishes its recommendations. If you would like to report 
a problem confidentially to these organizations, go to the ISMP 
Web site (www.ismp.org) for links with USP, ISMP, and FDA. 
Or call 1-800/23-ERROR to report directly to the USP-ISMP 
Medication Errors Reporting Program. ISMP address: 1800 
Byberry Rd, Huntingdon Valley, PA 19006. Phone: 215/947-
7797. E-mail: ismpinfo@ismp.org. 
Problem: Numbers containing decimal points are a major 
source of error and, when misplaced, can lead to misinter-
pretation of prescriptions. Decimal points can be easily 
overlooked, especially on prescriptions that have been faxed, 
prepared on lined order sheets, or written or typed on carbon 
and no-carbon-required (NCR) forms (often used in hospitals 
and long-term care facilities). If a decimal point is missed, 
an overdose may occur. The importance of proper decimal 
point placement and prominence cannot be overstated. 
For one, a decimal point should always be preceded by a 
whole number and never be left “naked.” Decimal expres-
sions of numbers less than one should always be preceded 
by a zero (0) to enhance the visibility of the decimal. For 
example, without a leading zero, a prescription for “Haldol® 
.5 mg” (see image shown on next page) was misinterpreted 
and dispensed as “Haldol 5 mg.” We have received similar 
reports with Risperdal® (risperidone) in which “Risperdal 
.5 mg” was prescribed (instead of Risperdal 0.5 mg), but 
the patient received several 5 mg doses because the decimal 
point was overlooked.
In addition, a whole number should never be followed with a 
decimal point and a zero. These “trailing zeros” (eg, “3.0”) are 
a frequent cause of 10-fold overdoses and should never be used. 
For example, when prescriptions have been written for “Couma-
din® 1.0 mg,” patients have received 10 mg in error. Similarly, 
a prescription for “Synthroid® 25.0 mcg” could be misread as 
“Synthroid 250 mcg.”
Dangerous use of decimals can also be problematic if they 
appear in electronic order entry systems or on computer-
generated labels. A newly admitted hospital patient told her 
physician that she took Phenobarbital® 400 mg PO three 
times daily. Subsequently, the physician wrote an order for 
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the drug in the dose relayed by the patient. A nurse saw the 
prescription vial and verified that this was the correct dose. 
However, prior to dispensing, a hospital pharmacist investi-
gated the unusually high dose. When he checked the prescrip-
tion vial, he found 
that it was labeled 
as “phenobarbital 
32.400MG tab-
le t .”  The label 
indicated that 30 
tablets were dis-
pensed with instructions to take one tablet three times daily. 
The hospital pharmacist contacted the outpatient pharmacy 
and suggested that the computer expressions including trail-
ing zeros be changed to avoid serious medication errors. 
The pharmacy management agreed that trailing zeros ap-
pearing on labels might pose a risk and made the change 
immediately.
Safe Practice Recommendations
In order to avoid misinterpretations due to decimal point 
placement, pharmacists should consider the following:
 Always include a leading zero for dosage strengths or con-
centrations less than one.  
 Never follow a whole number with a decimal point and a 
zero (trailing zero).
 Educate staff about the dangers involved with expressing 
doses using trailing zeros and naked decimal points.
 Eliminate dangerous decimal dose expressions from phar-
macy and prescriber electronic order entry screens, computer-
generated labels, preprinted prescriptions, etc.
 Avoid using decimals whenever a satisfactory alternative 
exists. For example, use 500 mg in place of 0.5 gram, 125 
mcg instead of 0.125 mg, or 2 ½ mg instead of 2.5 mg.
 Identify drugs with known 10-fold differences in dosage 
strength (eg, Cytomel® 5 mcg and 50 mcg, Coumadin 1 mg and 
10 mg, levothyroxine 25 mcg and 250 mcg) and place remind-
ers in electronic order entry systems and on pharmacy shelves 
to alert practitioners to double-check the dosage strength.
 When sending and receiving prescriptions via fax, health care 
practitioners should keep in mind that decimal points can be 
easily missed due to “fax noise.” Whenever possible, encourage 
prescribers to give original prescriptions (with an indication that 
it has been faxed) to their patients to take to the pharmacy for 
verification. Pharmacists should carefully review faxed prescrip-
tions and clarify prescriptions that contain fax noise. 
 Eliminate the lines on the back copy of NCR forms so that 
a person receiving can clearly see decimal points or other 
marks that were made on the top copy.
 Notify prescribers of the potential for error if misinterpreta-
tions due to decimal point usage are discovered.
DEA Issues Final Rules for Electronic 
Orders for Controlled Substances
On April 1, 2005, Drug Enforcement Administration (DEA) 
issued final rules regarding electronic orders for controlled 
substances. DEA revised its regulations to provide an electronic 
equivalent to the DEA official order form (Form 222), which is 
legally required for all distributions involving Schedule I and II 
controlled substances. The regulations will allow, but not require, 
registrants to order Schedule I and II substances electronically and 
maintain the records of these orders electronically. The regulations 
will reduce paperwork and transaction times for DEA registrants 
who handle, sell, or purchase Schedule I or II controlled sub-
stances. The effective date of the final rules was May 31, 2005. 
The final rules were issued via the Federal Register 
on April 1, 2005, and may be downloaded from the fol-
lowing Web site address: www.access.gpo.gov/su_docs/ 
fedreg/a050401c.html.
FDA Publishes Final Rule on 
Chlorofluorocarbons in Metered Dose 
Inhalers
FDA announced that albuterol metered-dose inhalers (MDI) 
using chlorofluorocarbon propellants must no longer be pro-
duced, marketed, or sold in the US after December 31, 2008.
The Health and Human Services (HHS) is encouraged that 
the manufacturers of three environmentally friendly albuterol 
inhalers are implementing programs to help assure access to these 
albuterol MDI for patients for whom price could be a significant 
barrier to access to this important medicine. These programs 
include MDI giveaways, coupons for reducing the price paid, 
and patient assistance programs based on financial need.
In a final rule, published March 31, 2005, in the Federal Register, 
HHS stated that sufficient supplies of two approved, environmentally 
friendly albuterol inhalers will exist by December 31, 2008, to allow 
the phasing out of similar, less environmentally friendly versions.
FDA Develops PSAs to Educate Consumers 
About Purchasing Medications Online
FDA recently released two public service announcement   (PSA) 
brochures, which educate consumers about the advantages and 
disadvantages of purchasing medication online. The brochures also 
advise consumers to ensure a Web site is a US-licensed pharmacy 
by contacting their state board of pharmacy. Consumers may want 
to refer to the list of Verified Internet Pharmacy Practice Sites™ 
(VIPPS®) on www.nabp.net to find out if a Web site has been 
checked to make sure it it has met state and federal rules. Consum-
ers also will know if an online pharmacy is VIPPS-accredited when 
they notice the VIPPS Seal on that particular Web site.
For more information on these PSAs visit www.fda.gov/cder/
consumerinfo/Buy_meds_online_all_resources.htm.
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Recommendation: NABP will work with stakeholders to 
create and implement national patient safety goals targeted 
specifically for community pharmacy practice.
Recommendation: NABP will incorporate specific 
competency statements regarding patient safety into the 
North American Pharmacist Licensure ExaminationTM  and a 
similar request to incorporate into the Pharmacy Technician 
Certification Examination.
As you can see we continue to work on patient safety 
initiatives in Massachusetts and nationally.
For a complete list of the recommendations, visit 
www.nabp.net.
3. Pharmacy Technician Update
To date, the Massachusetts Board of Registration in 
Pharmacy has registered 6,450 pharmacy technicians, many 
of whom are also certified by the Pharmacy Technician Cer-
tification Board (PTCB). PTCB’s governing organizations 
are the American Pharmacists Association, the American 
Society of Health-System Pharmacists, the Illinois Council 
on Health-System Pharmacists, the Michigan Pharmacists 
Association, and NABP. Visit www.ptcb.org.
4. Board Adopts New Regulations to 
Improve Patient Outcomes 
This article also appeared in the April 2005 Newsletter. 
On January 14, 2005, regulations became effective that 
will require all pharmacies operating in Massachusetts to es-
tablish “Continuous Quality Improvement (CQI) Programs” 
by December 31, 2005. These regulations may be found 
on the Board’s Web site at: www.mass.gov/dpl/boards/ph/
cmr/24715.htm.
These mandated programs will require each pharmacy 
to establish a CQI program “for the purpose of detecting, 
documenting, assessing and preventing Quality-Related 
Events (QREs).” At a minimum, a CQI program shall in-
clude provisions to designate an individual or individuals 
responsible for monitoring CQI program compliance with 
the requirements of 247 CMR 15.00; identify and document 
QREs; minimize impact of QREs on patients, analyze data 
collected in response to QREs to assess causes and any con-
tributing factors; use the findings of the analysis to formulate 
an appropriate response and develop pharmacy systems and 
workflow processes designed to prevent QREs; and provide 
ongoing professional education at least annually in the area 
of CQI to pharmacy personnel. The Board encourages any-
one with questions about how to establish a CQI program to 
contact the Board’s CQI Coordinator, Leo McKenna, RPh, 
PharmD, at leo.mckenna@state.ma.us or 617/973-0953.
5. Patient Safety Tips Of The Month
By Karen Ryle, President
1. Look-alike, sound-alike drug errors with Reminyl 
and Amaryl causes name change
Mixups between Reminyl®(galantamine) and Ama-
ryl® (glimepiride) have contributed to a name change in 
Reminyl. At first glance, Amaryl and Reminyl may seem 
sufficiently different, but when poorly handwritten, they 
look remarkably similar.
The overlapping dosage strength (4 mg) and frequency 
of dosing likely contributed to these errors. The adverse 
events caused by the mix-ups included severe hypoglyce-
mia and hypoglycemia-associated complications.
According to Ortho-McNeil Neurologics, Inc, two 
deaths have been reported where Amaryl was incorrectly 
dispensed and administered instead of the prescribed 
Reminyl.
Ortho-McNeil announced in April that it will soon 
market galantamine under the brand name Razadyne® in 
an effort to stop mix-ups between the Alzheimer’s disease 
product and the diabetes drug Amaryl.
2. Important need for Patient Counseling
FDA has recently alerted health care providers involving 
the inadvertent oral administration of Foradil Aerolizer and 
Spiriva HandiHaler capsules for inhalation. In total FDA has 
received 32 cases. Although most cases did not indicate an 
adverse event, one case reported difficulty breathing fol-
lowing oral ingestion, one reported hospitalization due to 
chronic obstructive pulmonary disease exacerbation, and 
there was one unrelated death.
The unintentional oral administration stems from the fact 
that these capsules resemble those typically taken orally. 
Swallowing the capsules for inhalation, rather than using 
the capsule via the appropriate inhalation device may lead 
to delayed onset of action, reduce efficacy, and inadequate 
drug delivery.
While FDA is working with the manufacturer on label-
ing and packaging changes to minimize potential user er-
ror and maximize patient safety, FDA offers the following 
suggestions:
 Counsel the patient about potential confusion and ways 
to avoid it.
 Advise health care providers to avoid dispensing the 
capsules for inhalation separately from the inhalation 
device.
 Advise patients who are using oral medication to store 
the capsules for inhalation together with the inhaler 
in a location where the capsules are unlikely to be 
confused with the oral medications.
 Circle or otherwise highlight the “For Inhalation Use 
Only” statement on the product package and container 
if possible.
For more information, please visit www.fda.gov.
6. NABP Announces Pharmacist  
Self-Assessment Mechanism 
The Pharmacist Self-Assessment Mechanism™ (PSAM™) 
is an evaluation tool intended to assist pharmacists in obtain-
ing objective, non-punitive feedback on their knowledge base. 
The PSAM consists of 100 multiple-choice questions and is 
divided into three sections of equal length. It costs $75 to take 
the PSAM. Pharmacists who complete all three sections of 
the PSAM will receive a Record of Completion stating their 
name and date of completion. The pharmacist should print 
this report and keep it for his or her records. 
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Question: Who should take the PSAM? 
Answer: The PSAM is applicable to general pharmacy 
practitioners in all settings. However, anyone who is interested 
may register and take the PSAM. There are no eligibility 
requirements to take the PSAM. 
Question: How do pharmacists benefit from 
the PSAM?
Answer: To benefit pharmacists and serve as a learning tool, 
the end of each section offers a feedback loop, which displays 
each question, the answer selected, the correct answer, a brief 
rationale, and a reference where more information relating to 
the topic may be obtained. 
Question: How is performance on the PSAM 
evaluated?
Answer: Upon completion of the PSAM, pharmacists will 
receive an unidentified Achievement Report indicating the 
percentage of questions answered correctly in each of the five 
content areas as well as the overall percentage of questions 
answered correctly. The Achievement Report is separate from 
the Record of Completion and has no identifiers of the test 
taker. Neither the Achievement Report nor the Record of 
Completion will be provided to any other party. 
Question: Do pharmacists get to review the questions?
Answer: Yes, pharmacists will be able to review the ques-
tions in the feedback loop. However, “going back” during 
the PSAM is not permitted. For additional information please 
visit NABP’s Web site at www.nabp.net.
7. Massachusetts Professional 
Recovery System 
Program for Chemically Dependent  
Pharmacists and Allied Health Professionals 
“Licensed professionals reaching out to help other licensed 
professionals cope with alcohol and drug problems”
For confidential information please contact Massachu-
setts Professional Recovery System Coordinator (MPRS) 
Tim McCarthy at 617/973-0910, or visit the MPRS Web 
site at www.mass.gov/dpl/services/mprs.htm.
8. Patient Adherence: ‘A Shared 
Responsibility’
By Leo McKenna, PharmD, CQI Surveyor, and
Jennifer Q. Weng, PharmD Candidate, MCPHS
Patient medication adherence is a major concern in 
today’s health care delivery system. Patient adherence stud-
ies have shown that medication non-adherence can lead to 
unnecessary hospitalization and preventable harm to the 
patient, which can also have a substantial impact on health 
care costs.1 Approximately $100 billion annually in direct 
and indirect costs are attributed to patient non-adherence.2 
Non-adherence can result from a variety of factors such as 
the cost of medications, the duration of therapy, and poor 
prescriber communication leading to under- or over-utiliza-
tion of a medication to name a few.3 Patients need to be edu-
cated about the benefits of properly taking their prescribed 
medication. The pharmacist can play a vital role in the shared 
responsibility of promoting patient adherence by educating 
the patient and monitoring prescription adherence. Providing 
patients with accurate information on the “why, what, and 
how” to properly take a medication helps promote reassur-
ance and confirmation of reasonable expectations. 
Patient counseling is an important function that should 
be performed on all new and refilled prescriptions. It allows 
the pharmacist to educate the patient on the proper use of 
his or her medication, what outcomes to expect, and how to 
react should adverse side effects occur. Counseling not only 
provides patient education, but it also allows the pharmacist 
to monitor for patient adherence so vital adjustments can 
be made to ensure safe continuance of therapy. In addition 
to patient counseling, pharmacists should also employ dif-
ferent strategies to help improve patient adherence. These 
strategies can include the use of refill reminder phone calls 
or e-mails, the use of pill organizers or medication reminder 
charts, and reinforcement.2  The pharmacists’ impact in re-
ducing unnecessary hospitalizations and associated costs is 
enormous and can only be achieved one patient at a time. 
This one-on-one relationship with patients will build a strong 
ongoing trust that will promote individual health and cre-
ate long-lasting relationships that will also strengthen our 
profession. Building alliances with consumers also serves 
the interest of making them better partners in their drug 
therapy.
1 World Health Organization. Adherence to Long-term 
Therapies: Evidence for Action, Genevea Switzerland: 
WHO; 2003. Available at www.who./int/chronic_condi-
tions/adherencereport/en. Accessed June 1, 2005.
2 APhA. Medication Compliance-Adherence-Persistence 
(CAP) Digest. Washington, DC: APhA; 2003.
3 APhA, Highlights Newsletter , October 2004, 
Volume 7, Number 4.
9. Compounded Events While 
Compounding a Prescription 
Leo McKenna, PharmD, CQI Surveyor, and
Jason Arruda, PharmD Candidate, Northeastern 
University
A recent Quality Related Event (QRE) reported to the 
Board, involving a compounded prescription that called 
for hydrocortisone powder as the active ingredient, was 
inadvertently compounded with testosterone powder. This 
unfortunate error resulted in harm to a 21-month-old male 
who experienced various adverse effects consistent with 
the diagnosis of precocious sexual development. This QRE 
serves as a reminder to pharmacists that all staff involved in 
compounding should be trained on a continuous basis in prop-
er techniques of compounding and to incorporate adequate 
safety barriers when compounded products are requested. 
The same can be said by the United States Pharmacopoeia 
(USP) who, this July, will unveil a new Chapter that outlines 
Quality Control in Pharmacy Compounding.1
This QRE had several root contributors to systems involv-
ing product selection, product processing, product verifi-
cation and counseling. The first, product selection, involved 
look-alike products hydrocortisone powder and testosterone 
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powder that are packaged similarly causing a potential error 
in product selection. A safety barrier to consider would be 
the separation of products that have similar packaging or 
are considered high-alert ingredients. The implementation 
of such a barrier would add a “thinking step” to assure that 
the right product is selected. Product preparation: before a 
product is prepared all ingredients should be checked against 
the ingredients listed on the original prescription confirm-
ing that proper ingredients and concentrations have been 
selected. Verification process: This QRE enforces the idea 
that during the verification process all ingredients follow 
the finished compounded prescription with corresponding 
strengths, quantities, and calculations utilized. This provides 
an additional quality assurance check that the proper ingre-
dients and concentrations were executed during product 
preparation. Counseling: the provision to counsel a patient 
or patient’s agent, is an opportunity to discuss the expected 
benefits, possible negative outcomes and proper adherence 
to a product as well as answer questions and concerns the 
patient may have with the product. In this case counseling 
may have alerted the patient’s representative to call and 
discuss the negative outcomes that occurred earlier in the 
process of discovering the QRE and may have limited the 
time the patient was exposed to the unintended product. 
(Pharmacists should also be reminded that all compound-
ing activities must be in compliance with current USP 
standards [see 247 CMR §9.01(3)]).
1 Pharmacists’ Pharmocopeia, www.usp.org/products/
pharmacistsPharm.html
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